BCF-01: a novel gastrogenic probiotic for infection control.

The widespread prevalence of infection, particularly in China, contributes to the development of gastrointestinal diseases. Antibiotics have limitations, including adverse reactions and increased antibiotic resistance. Therefore, identification of novel gastrogenic probiotics capable of surviving the acidic gastric environment and effectively combating infection has potential in restoring gastric microbiota homeostasis. Five novel strains of human gastrogenic (BCF-01-05) were isolated from healthy gastric mucosa and characterized using 16S rDNA identification. Acid resistance, inhibition, and adherence to gastric epithelial cells were evaluated in experiments and the molecular mechanism explored in experiments. Among the gastric-derived strains, BCF-01 exhibited the strongest adhesion and inhibition, warranting further safety evaluation. Through 16S rRNA sequencing of a mouse model, BCF-01 was determined to significantly restore -associated gastric dysbiosis and increase the abundance of potential probiotic bacteria. Furthermore, BCF-01 enhanced mucosal tight junction protein expression and inhibited the TLR4-NFκB-pyroptosis signaling pathway in macrophages, as demonstrated by qRT-PCR and western blotting.These findings highlight the potential of BCF-01 in the prevention and control of infection. Specifically, treatment with BCF-01 effectively restored gastric microecology and improved -mediated mucosal barrier destruction while reducing inflammation through inhibition of the TLR4-NFκB-pyroptosis signaling pathway in macrophages. BCF-01 is a promising alternative to traditional triple therapy for infections, offering minimal side effects with high suitability for high-risk individuals.